These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 34060937)

  • 1. Week 4 Liver Fat Reduction on MRI as an Early Predictor of Treatment Response in Participants with Nonalcoholic Steatohepatitis.
    Jiang H; Chen HC; Lafata KJ; Bashir MR
    Radiology; 2021 Aug; 300(2):361-368. PubMed ID: 34060937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MRI Quantification of Placebo Effect in Nonalcoholic Steatohepatitis Clinical Trials.
    Nedrud MA; Chaudhry M; Middleton MS; Moylan CA; Lerebours R; Luo S; Farjat A; Guy C; Loomba R; Abdelmalek MF; Sirlin CB; Bashir MR
    Radiology; 2023 Mar; 306(3):e220743. PubMed ID: 36318027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib.
    Jayakumar S; Middleton MS; Lawitz EJ; Mantry PS; Caldwell SH; Arnold H; Mae Diehl A; Ghalib R; Elkhashab M; Abdelmalek MF; Kowdley KV; Stephen Djedjos C; Xu R; Han L; Mani Subramanian G; Myers RP; Goodman ZD; Afdhal NH; Charlton MR; Sirlin CB; Loomba R
    J Hepatol; 2019 Jan; 70(1):133-141. PubMed ID: 30291868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Agreement Between Magnetic Resonance Imaging Proton Density Fat Fraction Measurements and Pathologist-Assigned Steatosis Grades of Liver Biopsies From Adults With Nonalcoholic Steatohepatitis.
    Middleton MS; Heba ER; Hooker CA; Bashir MR; Fowler KJ; Sandrasegaran K; Brunt EM; Kleiner DE; Doo E; Van Natta ML; Lavine JE; Neuschwander-Tetri BA; Sanyal A; Loomba R; Sirlin CB;
    Gastroenterology; 2017 Sep; 153(3):753-761. PubMed ID: 28624576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicenter Validation of Association Between Decline in MRI-PDFF and Histologic Response in NASH.
    Loomba R; Neuschwander-Tetri BA; Sanyal A; Chalasani N; Diehl AM; Terrault N; Kowdley K; Dasarathy S; Kleiner D; Behling C; Lavine J; Van Natta M; Middleton M; Tonascia J; Sirlin C;
    Hepatology; 2020 Oct; 72(4):1219-1229. PubMed ID: 31965579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis.
    Harrison SA; Bashir MR; Lee KJ; Shim-Lopez J; Lee J; Wagner B; Smith ND; Chen HC; Lawitz EJ
    J Hepatol; 2021 Jul; 75(1):25-33. PubMed ID: 33581174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association Between Magnetic Resonance Imaging-Proton Density Fat Fraction and Liver Histology Features in Patients With Nonalcoholic Fatty Liver Disease or Nonalcoholic Steatohepatitis.
    Wildman-Tobriner B; Middleton MM; Moylan CA; Rossi S; Flores O; Chang ZA; Abdelmalek MF; Sirlin CB; Bashir MR
    Gastroenterology; 2018 Nov; 155(5):1428-1435.e2. PubMed ID: 30031769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of treatment response in non-alcoholic steatohepatitis using advanced magnetic resonance imaging.
    Lin SC; Heba E; Bettencourt R; Lin GY; Valasek MA; Lunde O; Hamilton G; Sirlin CB; Loomba R
    Aliment Pharmacol Ther; 2017 Mar; 45(6):844-854. PubMed ID: 28116801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of Hepatic Steatosis in Nonalcoholic Fatty Liver Disease by Using Quantitative US.
    Han A; Zhang YN; Boehringer AS; Montes V; Andre MP; Erdman JW; Loomba R; Valasek MA; Sirlin CB; O'Brien WD
    Radiology; 2020 Apr; 295(1):106-113. PubMed ID: 32013792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial.
    Patel K; Harrison SA; Elkhashab M; Trotter JF; Herring R; Rojter SE; Kayali Z; Wong VW; Greenbloom S; Jayakumar S; Shiffman ML; Freilich B; Lawitz EJ; Gane EJ; Harting E; Xu J; Billin AN; Chung C; Djedjos CS; Subramanian GM; Myers RP; Middleton MS; Rinella M; Noureddin M
    Hepatology; 2020 Jul; 72(1):58-71. PubMed ID: 32115759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
    Harrison SA; Bashir MR; Guy CD; Zhou R; Moylan CA; Frias JP; Alkhouri N; Bansal MB; Baum S; Neuschwander-Tetri BA; Taub R; Moussa SE
    Lancet; 2019 Nov; 394(10213):2012-2024. PubMed ID: 31727409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial).
    Loomba R; Sirlin CB; Ang B; Bettencourt R; Jain R; Salotti J; Soaft L; Hooker J; Kono Y; Bhatt A; Hernandez L; Nguyen P; Noureddin M; Haufe W; Hooker C; Yin M; Ehman R; Lin GY; Valasek MA; Brenner DA; Richards L;
    Hepatology; 2015 Apr; 61(4):1239-50. PubMed ID: 25482832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Change in MRI-PDFF and Histologic Response in Patients With Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis.
    Stine JG; Munaganuru N; Barnard A; Wang JL; Kaulback K; Argo CK; Singh S; Fowler KJ; Sirlin CB; Loomba R
    Clin Gastroenterol Hepatol; 2021 Nov; 19(11):2274-2283.e5. PubMed ID: 32882428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Noninvasive Diagnosis of Nonalcoholic Fatty Liver Disease and Quantification of Liver Fat with Radiofrequency Ultrasound Data Using One-dimensional Convolutional Neural Networks.
    Han A; Byra M; Heba E; Andre MP; Erdman JW; Loomba R; Sirlin CB; O'Brien WD
    Radiology; 2020 May; 295(2):342-350. PubMed ID: 32096706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic accuracy of magnetic resonance imaging hepatic proton density fat fraction in pediatric nonalcoholic fatty liver disease.
    Middleton MS; Van Natta ML; Heba ER; Alazraki A; Trout AT; Masand P; Brunt EM; Kleiner DE; Doo E; Tonascia J; Lavine JE; Shen W; Hamilton G; Schwimmer JB; Sirlin CB;
    Hepatology; 2018 Mar; 67(3):858-872. PubMed ID: 29028128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inter-reader agreement of magnetic resonance imaging proton density fat fraction and its longitudinal change in a clinical trial of adults with nonalcoholic steatohepatitis.
    Hooker JC; Hamilton G; Park CC; Liao S; Wolfson T; Dehkordy SF; Hong CW; Mamidipalli A; Gamst A; Loomba R; Sirlin CB
    Abdom Radiol (NY); 2019 Feb; 44(2):482-492. PubMed ID: 30128694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MRI Assessment of Treatment Response in HIV-associated NAFLD: A Randomized Trial of a Stearoyl-Coenzyme-A-Desaturase-1 Inhibitor (ARRIVE Trial).
    Ajmera VH; Cachay E; Ramers C; Vodkin I; Bassirian S; Singh S; Mangla N; Bettencourt R; Aldous JL; Park D; Lee D; Blanchard J; Mamidipalli A; Boehringer A; Aslam S; Leinhard OD; Richards L; Sirlin C; Loomba R
    Hepatology; 2019 Nov; 70(5):1531-1545. PubMed ID: 31013363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of noninvasive quantitative decline in liver fat content on MRI with histologic response in nonalcoholic steatohepatitis.
    Patel J; Bettencourt R; Cui J; Salotti J; Hooker J; Bhatt A; Hernandez C; Nguyen P; Aryafar H; Valasek M; Haufe W; Hooker C; Richards L; Sirlin CB; Loomba R
    Therap Adv Gastroenterol; 2016 Sep; 9(5):692-701. PubMed ID: 27582882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MRI proton density fat fraction is robust across the biologically plausible range of triglyceride spectra in adults with nonalcoholic steatohepatitis.
    Hong CW; Mamidipalli A; Hooker JC; Hamilton G; Wolfson T; Chen DH; Fazeli Dehkordy S; Middleton MS; Reeder SB; Loomba R; Sirlin CB
    J Magn Reson Imaging; 2018 Apr; 47(4):995-1002. PubMed ID: 28851124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Role of Three-Dimensional Magnetic Resonance Elastography in the Diagnosis of Nonalcoholic Steatohepatitis in Obese Patients Undergoing Bariatric Surgery.
    Allen AM; Shah VH; Therneau TM; Venkatesh SK; Mounajjed T; Larson JJ; Mara KC; Schulte PJ; Kellogg TA; Kendrick ML; McKenzie TJ; Greiner SM; Li J; Glaser KJ; Wells ML; Chen J; Ehman RL; Yin M
    Hepatology; 2020 Feb; 71(2):510-521. PubMed ID: 30582669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.